Shigeo Ohba

8PUBLICATIONS
11CO-AUTHORS
Molecular targetsPacific Peoples life coursePredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 29, 2025
Targeting distinct amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas.

Shigeo Ohba, Akiyoshi Hirayama, Takao Teranishi

|Jan 11, 2025
Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy.

Shigeo Ohba, Takao Teranishi, Kazuyasu Matsumura

|Feb 11, 2023
Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma.

Shigeo Ohba, Kazuhiro Murayama, Takao Teranishi

|Jun 02, 2021
Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells.

Shigeo Ohba, Kei Yamashiro, Yuichi Hirose

|May 06, 2021
RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells.

Joydeep Mukherjee, Ajay Pandita, Chatla Kamalakar

|Feb 06, 2020
L-asparaginase and 6-diazo-5-oxo-L-norleucine synergistically inhibit the growth of glioblastoma cells.

Shigeo Ohba, Yuichi Hirose

Pageof 2

Frequent Collaborators

3 joint publications

Yuichi Hirose

2 joint publications

Russell O Pieper

1 joint publications

Ajay Pandita

1 joint publications

Chatla Kamalakar